MX2022005104A - Métodos terapéuticos mediante el uso de vadadustat. - Google Patents
Métodos terapéuticos mediante el uso de vadadustat.Info
- Publication number
- MX2022005104A MX2022005104A MX2022005104A MX2022005104A MX2022005104A MX 2022005104 A MX2022005104 A MX 2022005104A MX 2022005104 A MX2022005104 A MX 2022005104A MX 2022005104 A MX2022005104 A MX 2022005104A MX 2022005104 A MX2022005104 A MX 2022005104A
- Authority
- MX
- Mexico
- Prior art keywords
- patients
- ckd
- vadadustat
- anemia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención proporciona métodos para el tratamiento de la anemia en pacientes con enfermedad renal crónica (CKD) mediante el uso de vadadustat (Compuesto 1), que incluyen los métodos adecuados para la terapia de conversión, corrección y mantenimiento para pacientes. Por ejemplo, los métodos descritos en la presente descripción son duraderos, con eficacia observada durante 24-52 semanas. Los métodos descritos en la presente descripción pueden ser particularmente beneficiosos para los pacientes que se convierten desde un tratamiento previo para la anemia que comprende la administración de un agente estimulante de la eritropoyetina (ESA) tal como darbepoyetina alfa (DA), pacientes con CKD en diálisis (por ejemplo, diálisis peritoneal o hemodiálisis) o pacientes con CKD que tienen determinados niveles de hemoglobina (Hb).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928994P | 2019-10-31 | 2019-10-31 | |
| US201962931458P | 2019-11-06 | 2019-11-06 | |
| US201962933077P | 2019-11-08 | 2019-11-08 | |
| US202063073612P | 2020-09-02 | 2020-09-02 | |
| PCT/US2020/058007 WO2021087144A1 (en) | 2019-10-31 | 2020-10-29 | Therapeutic methods using vadadustat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005104A true MX2022005104A (es) | 2022-07-21 |
Family
ID=75716456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005104A MX2022005104A (es) | 2019-10-31 | 2020-10-29 | Métodos terapéuticos mediante el uso de vadadustat. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230285374A1 (es) |
| EP (1) | EP4051262A1 (es) |
| JP (1) | JP2023501221A (es) |
| KR (1) | KR20220133176A (es) |
| CN (1) | CN115003297A (es) |
| AU (1) | AU2020374963A1 (es) |
| BR (1) | BR112022008484A2 (es) |
| CA (1) | CA3159368A1 (es) |
| IL (1) | IL292502A (es) |
| MX (1) | MX2022005104A (es) |
| TW (1) | TW202128157A (es) |
| WO (1) | WO2021087144A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016537365A (ja) | 2013-11-15 | 2016-12-01 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用 |
| AR114886A1 (es) | 2018-05-09 | 2020-10-28 | Akebia Therapeutics Inc | Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético |
| AU2022206302A1 (en) * | 2021-01-08 | 2023-08-17 | Akebia Therapeutics, Inc. | Therapeutic methods using vadadustat |
| CN113855638B (zh) * | 2021-10-28 | 2023-06-09 | 北京福元医药股份有限公司 | 一种罗沙司他药物制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3007695T3 (da) | 2013-06-13 | 2024-03-18 | Akebia Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af anæmi |
| HRP20211862T1 (hr) | 2015-04-01 | 2022-03-04 | Akebia Therapeutics, Inc. | Pripravci za i postupci liječenja anemije |
-
2020
- 2020-10-29 MX MX2022005104A patent/MX2022005104A/es unknown
- 2020-10-29 KR KR1020227017323A patent/KR20220133176A/ko unknown
- 2020-10-29 JP JP2022525348A patent/JP2023501221A/ja active Pending
- 2020-10-29 BR BR112022008484A patent/BR112022008484A2/pt unknown
- 2020-10-29 AU AU2020374963A patent/AU2020374963A1/en active Pending
- 2020-10-29 CA CA3159368A patent/CA3159368A1/en active Pending
- 2020-10-29 WO PCT/US2020/058007 patent/WO2021087144A1/en active Application Filing
- 2020-10-29 EP EP20811859.6A patent/EP4051262A1/en active Pending
- 2020-10-29 CN CN202080091841.1A patent/CN115003297A/zh active Pending
- 2020-10-29 US US17/772,856 patent/US20230285374A1/en active Pending
- 2020-10-30 TW TW109137864A patent/TW202128157A/zh unknown
-
2022
- 2022-04-25 IL IL292502A patent/IL292502A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115003297A (zh) | 2022-09-02 |
| EP4051262A1 (en) | 2022-09-07 |
| AU2020374963A1 (en) | 2022-06-09 |
| JP2023501221A (ja) | 2023-01-18 |
| TW202128157A (zh) | 2021-08-01 |
| BR112022008484A2 (pt) | 2022-07-19 |
| KR20220133176A (ko) | 2022-10-04 |
| US20230285374A1 (en) | 2023-09-14 |
| WO2021087144A1 (en) | 2021-05-06 |
| CA3159368A1 (en) | 2021-05-06 |
| IL292502A (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005104A (es) | Métodos terapéuticos mediante el uso de vadadustat. | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| WO2012115771A3 (en) | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides | |
| EP4233861A3 (en) | Compositions for treatment of essential tremor | |
| MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| EP3773880A4 (en) | Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods | |
| MX2022004012A (es) | Solucion de bloqueo de cateter y terapia de bloqueo de cateter. | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| EP4316589A3 (en) | Treatment of patients with classic fabry disease | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| MX2021015352A (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. | |
| MX2021012894A (es) | Compuestos ciclicos de fosfato. | |
| BR112023002458A2 (pt) | Métodos de tratamento da gota | |
| WO2009152070A3 (en) | Intradialytic administration of sodium thiosulfate | |
| WO2020079489A3 (en) | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs | |
| JOP20170040B1 (ar) | مركب لخفض جلوكوز الدم | |
| EA202090558A1 (ru) | Схемы лечения | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| PH12018501769A1 (en) | Medicament for treatment of diabetic foot infections | |
| MX2007003120A (es) | Metodo y composicion para el tratamiento de pacientes que se someten a dialisis de rinon. | |
| EP4084764A4 (en) | VENOUS BLOOD FLOW STIMULATOR FOR EXTRACORPORAL THERAPY | |
| EP4327869A3 (en) | Methods of treating fabry patients having renal impairment | |
| MX2019008076A (es) | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. |